PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Phenotype | |brain metastases |
| Sentences | 97 |
| PubMedID- 23462853 | The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. |
| PubMedID- 24244833 | brain metastases of invasive breast cancer are associated with 1 and 2 year survival rate of 20% and <2% respectively. |
| PubMedID- 23115660 | Objective: the objective of study is to evaluate the incidence of leptomeningeal carcinomatosis (lmc) in breast cancer patients with parenchymal brain metastases (pbm) and clinical risk factors for the development of lmc. |
| PubMedID- 25472758 | Conclusions: in breast cancer patients with few brain metastases, radiosurgery plus whole-brain radiotherapy resulted in significantly better freedom from new brain metastases than radiosurgery alone. |
| PubMedID- 23028253 | The same number of publications covered surgical or radiosurgical approaches and 3 brain metastases in patients with breast cancer. |
| PubMedID- 25528021 | The clinical course and prognostic factors of her2-positive breast cancer patients with brain metastases are not well known because of the relatively small population. |
| PubMedID- 21472708 | Background: brain metastases (bm) arising from triple-negative breast cancer (tnbc) portend a poor prognosis. |
| PubMedID- 22024205 | Purpose: to analyze factors affecting outcomes in breast cancer patients with brain metastases (bm) and characterize the role of her2 status. |
| PubMedID- 26472289 | Calcification of brain metastases in patients with breast cancer is very rare. |
| PubMedID- 26463521 | Strategies designed to treat brain metastases of breast cancer, particularly chemotherapeutics such as irinotecan, demonstrate limited efficacy. |
| PubMedID- 24312053 | To determine btb passive permeability and whether p-gp influences r123 uptake into brain metastases of breast cancer, tumor-bearing mice were injected with 14c-aib (passive permeability tracer) which was allowed to circulate for 10 min before a 2 min r123 perfusion, which was followed by sacrifice (figure 3). |
| PubMedID- 24614081 | Enumeration of tumor cells in the peripheral blood (circulating tumor cells, ctc) and csf (cerebrospinal fluid tumor cells, csftc) of nine breast cancer patients with brain metastases revealed dynamic changes in tumor cell burden in both the peripheral blood and csf compartments that correlated with clinical disease progression. |
| PubMedID- 25075060 | We describe the case of an elderly woman affected by triple-negative breast cancer with bone and brain metastases who has been treated for five years with metronomic capecitabine. |
| PubMedID- 26482599 | Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy. |
| PubMedID- 22516807 | Validity of three recently proposed prognostic grading indexes for breast cancer patients with radiosurgically treated brain metastases. |
| PubMedID- 20525352 | Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. |
| PubMedID- 26109921 | Methods: a breast cancer patient with 8 brain metastases was treated on the brain by a radical rt regimen. |
| PubMedID- 22132754 | Overall survival by pten status as determined by brain metastases immunohistochemistry in patients with triple-negative breast cancer. |
| PubMedID- 25106661 | To define prognostic factors for breast cancer patients with brain metastases, compare their clinical courses and prognoses according to breast cancer subtypes, and analyze the causes of death in such patients. |
| PubMedID- 22127284 | Impact of anti-her2 therapy on overall survival in her2-overexpressing breast cancer patients with brain metastases. |
| PubMedID- 19951956 | Long-term survivors among breast cancer patients with brain metastases. |
| PubMedID- 22700320 | brain metastases frequently occur in patients with advanced breast cancer.effective treatment strategies are therefore needed against brain metastasis from breast carcinoma. |
| PubMedID- 21209717 | The annual incidence of brain metastases in patients with breast cancer is in the range of 4–11 per 100.000 persons per year. |
| PubMedID- 22915160 | The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival. |
| PubMedID- 23335064 | Methods: of 405 metastatic breast cancer patients with brain metastases at referral centers in turkey, 46 were treated with lapatinib plus capecitabine only after the development of brain metastasis. |
| PubMedID- 20549816 | Methods: the group of 420 consecutive breast cancer patients with brain metastases treated at the same institution between the years of 2003 to 2009 was analyzed. |
| PubMedID- 23665199 | Current standard systemic therapies for treating breast cancer patients with brain metastases are inefficient. |
| PubMedID- 23667803 | (a)time to brain metastases from diagnosis of primary breast cancer according to subtype and trastuzumab administration before brain metastases development. |
| PubMedID- 23205151 | Here, we show that this ability can be exploited to deliver both diagnostic and therapeutic nanoparticles specifically to experimental brain metastases of breast cancer. |
| PubMedID- 24761771 | brain metastases-free survival of breast cancer patients with er negative versus er positive tumors. |
| PubMedID- 24176086 | Inpatient stays coded as breast cancer (c50) with brain metastases (c79.3) were selected. |
| PubMedID- 23827085 | Aims: to document the type, location, extent, and complications of brain metastases in patients with breast cancer and identify associations with oestrogen receptor (er) negative and human epidermal growth factor receptor 2 (her-2) receptor expression. |
| PubMedID- 22333639 | The combination treatment of paclitaxel and capecitabine is considered to be effective for metastatic breast cancer with brain metastases. |
| PubMedID- 25564062 | Objective: to analyze the clinical characteristics and survival depending on biological subtypes in breast cancer patients with brain metastases (bm). |
| PubMedID- 22638937 | [radiotherapy and re-irradiation of breast cancer patients with brain metastases: survival in the trastuzumab era]. |
| PubMedID- 25893587 | Minimal research has been conducted on the risk factors for and incidence of brain metastases in women with inflammatory breast cancer (ibc). |
| PubMedID- 23394467 | Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases. |
| PubMedID- 24740972 | After local treatment, the combination of weekly trastuzumab plus vinorelbine may be an effective alternative regimen in her-2 positive breast cancer patients with brain metastases. |
| PubMedID- 21160581 | Whole brain radiotherapy (wbrt) remains the standard management of breast cancer patients with brain metastases, allowing for symptomatic improvement and good local control in most patients. |
| PubMedID- 23650496 | brain metastases arising from breast cancer are a burgeoning clinical problem associated with decline in quality of life, loss of independence, and poor survival [1]. |
| PubMedID- 20004109 | The incidence of symptomatic brain metastases among women with metastatic breast cancer ranges from 10% to 16%. |
| PubMedID- 24294457 | Gkrs has shown to be an effective and safe treatment modality for treating brain metastases of primary breast cancer. |
| PubMedID- 22421776 | [a case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies]. |
| PubMedID- 23374226 | It is well accepted in the literature that blood vessels within brain metastases of breast cancer are more permeable than bbb microvessels, as they are characteristic of the breast tissue origin of the tumour cells causing substantial cerebral oedema [29,38-41]. |
| PubMedID- 25977884 | Lapatinib access into normal brain and brain metastases in patients with her-2 overexpressing breast cancer. |
| PubMedID- 23302543 | This is comparable to the median os of approximately 4 months reported in historical analyses of breast cancer patients with brain metastases [12,16-18]. |
| PubMedID- 23122784 | Methods: in this single-arm phase 2, open-label, multicentre study, eligible patients had her2-positive metastatic breast cancer with brain metastases not previously treated with wbrt, capecitabine, or lapatinib. |
Page: 1 2